AC Immune SA (NASDAQ: ACIU)

AC Immune SA is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic and diagnostic products for neurodegenerative diseases, particularly Alzheimer’s disease (AD), Parkinson’s disease (PD), and other related disorders. The company leverages its proprietary technology platforms, SupraAntigen and Morphomer, to create innovative treatments targeting protein misfolding and aggregation, which are central to the pathology of these diseases. AC Immune’s approach combines active immunotherapies, small molecule inhibitors, and diagnostic imaging agents to address unmet medical needs in the neurodegenerative space.

The company generates revenue through a combination of product development, licensing agreements, and collaborations with major pharmaceutical partners. Its primary products include ACI-35.030, an anti-Tau active immunotherapy for AD; ACI-24.060, an anti-Abeta active immunotherapy for AD and Down syndrome (DS); ACI-7104.056, an anti-alpha-synuclein (a-syn) active immunotherapy for PD and multiple system atrophy (MSA); and PI-2620, a Tau-PET tracer for diagnostic imaging. Additionally, AC Immune develops small molecule inhibitors under the Morphomer Tau program and diagnostic imaging agents like ACI-12589 and ACI-15916 for a-synucleinopathies. The company’s customer base includes pharmaceutical partners such as Janssen, Lilly, and Takeda, as well as regulatory bodies and healthcare providers involved in clinical trials and commercialization.

• Therapeutics: AC Immune’s therapeutic segment focuses on developing active immunotherapies and small molecule inhibitors. Key products include ACI-35.030 for AD, ACI-24.060 for AD and DS, and ACI-7104.056 for PD and MSA. The company also advances the Morphomer Tau program, which aims to inhibit Tau aggregation in AD and other tauopathies. These therapies target the underlying pathology of neurodegenerative diseases, offering potential disease-modifying treatments.

• Diagnostics: This segment involves the development of PET imaging agents for early and accurate diagnosis of neurodegenerative diseases. Key products include PI-2620 for Tau imaging, ACI-12589 and ACI-15916 for a-syn imaging, and ACI-19626 for TDP-43 imaging. These diagnostic tools are crucial for monitoring disease progression and assessing the efficacy of therapeutic interventions.

AC Immune operates in a highly competitive industry, facing challenges from both established pharmaceutical companies and emerging biotech firms. Key competitors include Eli Lilly, Biogen, and Eisai, which have developed approved disease-modifying therapies for AD. Other competitors in the active immunotherapy space include Axon Neuroscience, Nuravax, and TheraVac. AC Immune’s competitive advantages lie in its proprietary technology platforms, which enable the development of highly selective and effective therapies and diagnostics. The company’s strategic partnerships with major pharmaceutical firms provide access to extensive resources and expertise, accelerating the development and commercialization of its products.

The company’s customer base includes pharmaceutical partners such as Janssen, Lilly, and Takeda, which collaborate on the development and commercialization of AC Immune’s products. Additionally, regulatory bodies and healthcare providers involved in clinical trials and commercialization are key stakeholders. AC Immune’s focus on innovative therapies and diagnostics positions it as a significant player in the neurodegenerative disease market, with the potential to address critical unmet medical needs.